Integrated Biopharma INC 8-K filings

Integrated BioPharma, Inc. and its subsidiary Manhattan Drug Company, Inc. have amended their loan agreement with PNC Bank, extending a revolving line of credit and establishing a new convertible line of credit.

Integrated BioPharma, Inc. reported a net loss of $0.8 million for the quarter ended March 31, 2026, driven by a 27.3% decline in quarterly revenue.

Integrated BioPharma, Inc. announced an extension of its credit line with PNC Bank, moving the expiration date to July 14, 2026.

Integrated BioPharma, Inc. reported a net loss of $0.8 million for the quarter ended December 31, 2025, as revenue decreased by 10.3% to $11.3 million.

Integrated BioPharma, Inc. announced the results of its 2025 Annual Meeting, where stockholders elected a Class III director, approved executive compensation, and ratified the independent auditors.

Integrated BioPharma, Inc. reported a 6.6% decrease in revenue to $12.7 million for the quarter ended September 30, 2025, alongside declines in operating and net income.

Integrated BioPharma, Inc. announced increased revenues for both the fourth quarter and full fiscal year ended June 30, 2025, alongside improved annual net income.

Integrated BioPharma announces a 6.1% increase in revenue and improved operating income for the quarter ended March 31, 2025, compared to the same period in 2024.

Integrated BioPharma, Inc. announces the resignation of Marcum LLP as its independent registered public accounting firm and the engagement of CBIZ CPAs, effective April 24, 2025.

Integrated BioPharma, Inc. has entered into a loan agreement with PNC Bank, securing a $4.5 million credit facility to support working capital and equipment purchases.

Integrated BioPharma announces improved financial results for the quarter and six-month period ended December 31, 2024, with increased revenue and a shift to operating income.

Integrated BioPharma held its 2024 Annual Meeting, electing two Class I directors and ratifying the appointment of its independent auditors.

Integrated BioPharma, Inc. reports a profitable quarter with increased revenue and operating income compared to the same period last year.

Integrated BioPharma's fiscal year 2024 saw a slight decrease in revenue but an improvement in operating and net income compared to the previous year.

Integrated BioPharma reported flat revenue but increased operating and net income for the quarter ended March 31, 2024, while experiencing a net loss for the nine-month period.

Integrated BioPharma reported a decrease in revenue and increased operating losses for the quarter ended December 31, 2023, compared to the same period in 2022.